E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
After a baby is born, the placenta (afterbirth) should be delivered. Sometimes this does not occur and the placenta gets stuck. This medical condition is called a retained placenta. |
|
E.1.1.2 | Therapeutic area | Body processes [G] - Reproductive physiologi cal processes [G08] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 16.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10038757 |
E.1.2 | Term | Retained placenta |
E.1.2 | System Organ Class | 100000004868 |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 16.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10038350 |
E.1.2 | Term | Removal retained placenta |
E.1.2 | System Organ Class | 100000004865 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary research objectives of the internal pilot RCT are: 1) To demonstrate trial processes for approaching women, gaining consent, randomising, treating and assessing outcomes are optimal, and to implement improvements as required; 2) To determine achievable recruitment rates; 3) To determine the likely effect size, to inform a calculation on whether the planned sample size can be reduced whilst maintaining study power; 4) To pilot and modify if required the post-partum questionnaires (assessment of patient satisfaction and collection of health service use outcomes).
The primary research objectives of the substantive GOT-IT RCT are: 1) To determine the clinical effectiveness of sublingual GTN in treating RP and avoiding MROP in women with vaginal delivery following failure of current management (defined as a third stage of labour lasting more than 30 mins after active management or 60 mins after physiological followed by active management respectively) (clinical domain);
|
|
E.2.2 | Secondary objectives of the trial |
The secondary objective is to assess NHS costs in relation to the primary outcome and range of secondary outcomes expected to differ between arms of the trial, using a cost-consequence balance sheet approach. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Women with Retained Placenta. - Women aged 16 or over. • Women with vaginal delivery (including women with a previous caesarean section). • Haemodynamically stable (systolic blood pressure more than 100mg Hg and pulse less than 110 beats per min). • > 14 weeks gestation. |
|
E.4 | Principal exclusion criteria |
• Unable to give informed consent. • Suspected placenta accreta/increta/percreta. • Multiple pregnancy. • Women having an instrumental vaginal delivery. • Allergy or hypersensitivity to nitrates or any other constituent of the formulation. • Taken alcohol in the last 24 hours. • Concomitant use with phosphodiesterase inhibitors (such as sildenafil, tadalafil, or vardenafil). • Currently participating in another CTIMP. - Contra-indication due to one of the following: Severe anaemia, constrictive pericarditis, extreme bradycardia, incipient glaucoma, Glucose-6-phosphatedehydrogenase-deficiency, cerebral haemorrhage and brain trauma, aortic and / or mitral stenosis and angina caused by hypertrophic obstructive cardiomyopathy. Circulatory collapse, cardiogenic shock and toxic pulmonary oedema. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Primary outcomes will be measured over four interrelated domains of clinical, safety, patientsided and economic. 1) Clinical: need for MROP, defined as the placenta remaining undelivered 15 minutes post study treatment and/or being required within 15 minutes of treatment due to safety concerns. 2) Safety: measured blood loss between administration of treatment and transfer to the postnatal ward or other clinical area (e.g. labour ward high dependency). 3) Patient-sided: satisfaction with treatment and side effect profile assessed by questionnaire. It will be informed by our qualitative studies and based on questionnaires we have previously used to assess satisfaction.[22] 4) Economic: Net incremental costs (or cost savings) to the National Health Service of using GTN versus standard practice. Costs will include GTN (dose and time to administer drug, monitor woman and deliver the placenta if effective), MROP, and further health service resource use to six weeks postnatal (as measured by the health service resource use questionnaire). |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Please see timepoints specified above. |
|
E.5.2 | Secondary end point(s) |
Secondary outcomes will be measured over two interrelated domains of clinical and economic outcomes. The feasibility of the collection of secondary outcomes will be tested during the internal pilot phase. 1) Clinical outcomes: i) Fall in haemoglobin of more than 15% between recruitment and the first postnatal day; ii) time from randomisation to delivery of placenta; iii) MROP in theatre; iv) need for earlier than planned MROP on the basis of the clinical condition; v) fall in systolic or diastolic blood pressure of more than 15mmHg and/or increase in pulse of more than 20 beats/minute between baseline and 5 and 15 minutes postadministration of active/placebo treatment; vi) need for blood transfusion between time of delivery and discharge from hospital; vii) need for general anaesthesia; viii) maternal pyrexia (one or more temperature reading of more than 38°C within 72hrs of delivery or discharge from hospital if discharge occurs sooner); ix) sustained uterine relaxation after removal placenta requiring uterotonics; 2) Costs: The mean costs will be summarised by treatment allocation group, and the incremental cost (cost saving) associated with the use of GTN will be estimated using an appropriately specified general linear model. The cost data will be presented alongside the primary and secondary outcome data in a cost-consequence balance sheet, indicating which strategy each outcome favours. There are no secondary patient-sided or safety outcomes. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Please see timepoints specified above. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 20 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of the trial is defined as the return of the 6 week postnatal questionnaire by the last participant in the trial. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 5 |
E.8.9.1 | In the Member State concerned days | 31 |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 5 |
E.8.9.2 | In all countries concerned by the trial days | 31 |